Aptamers: from bench side research towards patented molecules with therapeutic applications

Bibliography

• Weiner GJ. Monoclonal antibody mechanisms of action in cancer. Immunol Res 2007;39:271-8
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S. Use of chemotherapy plus a monoclonal antibody against HERK2 for metastatic breast cancer that overexpress HER2. N Engl J Med 2001;344:783-92
   PubMed Web of Science ®Google Scholar
• Vogel CL, Cobleigh MA, Gutheil JC, Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26
   PubMed Web of Science ®Google Scholar
• de Groot JF, Yung WK. Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas. Cancer J 2008;14:279-85
   PubMed Web of Science ®Google Scholar
• Ulrich H, Martins AH, Pesquero JB. RNA and DNA aptamers in cytomics analysis. Cytometry A 2004;59:220-31
   PubMedGoogle Scholar
• Ulrich H, Trujillo CA, Nery AA, DNA and RNA aptamers: from tools for basic research towards therapeutic applications. Comb Chem High Throughput Screen 2006;9:619-32
   PubMed Web of Science ®Google Scholar
• Ulrich H, Wrenger C. Disease-specific biomarker discovery by aptamers. Cytometry A 2009; doi: 10.1002/cyto.a.20766
   Google Scholar
• Nery AA, Wrenger C, Ulrich H. Recognition of biomarkers and cell-specific molecular signatures: aptamers as capture agents. J Sep Sci 2009;32:1523-30
   PubMedGoogle Scholar
• Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990;249:505-10
   PubMed Web of Science ®Google Scholar
• Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature 1990;346:818-22
   PubMed Web of Science ®Google Scholar
• Blank M, Weinschenk T, Priemer M, Systematic evolution of a DNA aptamer binding to rat brain tumor microvessels selective targeting of endothelial regulatory protein pigpen. J Biol Chem 2001;276:16464-8
   PubMed Web of Science ®Google Scholar
• Ulrich H, Ippolito JE, Pagán OR, In vitro selection of RNA molecules that displace cocaine from the membrane-bound nicotinic acetylcholine receptor. Proc Natl Acad Sci USA 1998;95:14051-6
   PubMed Web of Science ®Google Scholar
• Ulrich H, Magdesian MH, Alves MJ, In vitro selection of RNA aptamers that bind to cell adhesion receptors of trypanosoma cruzi and inhibit cell invasion. J Biol Chem 2002;277:20756-62
   PubMed Web of Science ®Google Scholar
• Chu TC, Marks JWIII, Lavery LA, Aptamer: toxin conjugates that specifically target prostate tumor cells. Cancer Res 2006;66:5989-92
   PubMed Web of Science ®Google Scholar
• Chu TC, Twu KY, Ellington AD, Aptamer mediated siRNA delivery. Nucleic Acids Res 2006;34:e73
   PubMed Web of Science ®Google Scholar
• Guo KT, Schäfer R, Paul A, A new technique for the isolation and surface immobilization of mesenchymal stem cells from whole bone marrow using high-specific DNA aptamers. Stem Cells 2006;24:2220-31
   PubMed Web of Science ®Google Scholar
• Avci-Adali M, Paul A, Ziemer G, Wendel HP. New strategies for in vivo tissue engineering by mimicry of homing factors for self-endothelialisation of blood contacting materials. Biomaterials 2008;29:3936-45
   PubMed Web of Science ®Google Scholar
• Li N, Ebright JN, Stovall GM. Technical and biological issues relevant to cell typing with aptamers. J Proteome Res 2009;8:2438-48
   PubMed Web of Science ®Google Scholar
• de Smidt PC, Le Doan T, de Falco S, Association of antisense oligonucleotides with lipoproteins prolongs the plasma half-life and modifies the tissue distribution. Nucleic Acids Res 1991;19:4695-700
   PubMed Web of Science ®Google Scholar
• Pieken WA, Olsen DB, Benseler F, Kinetic characterization of ribonuclease-resistant 2′-modified hammerhead ribozymes. Science 1991;253:314-7
   PubMed Web of Science ®Google Scholar
• Eulberg D, Klussmann S. Spiegelmers: biostable aptamers. Chembiochem 2003;4:979-83
   PubMed Web of Science ®Google Scholar
• Jayasena SD. Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin Chem 1999;45:1628-50
   PubMed Web of Science ®Google Scholar
• Ruckman J, Green LS, Beeson J, 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 1998;273:20556-67
   PubMed Web of Science ®Google Scholar
• Pietras K, Rubin K, Sjöblom T, Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002;62:5476-84
   PubMed Web of Science ®Google Scholar
• Lupold SE, Hicke BJ, Lin Y, Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res 2002;62:4029-33
   PubMed Web of Science ®Google Scholar
• Biesecker G, Dihel L, Enney K, Bendele RA. Derivation of RNA aptamer inhibitors of human complement C5. Immunopharmacology 1999;42:219-30
   PubMed Web of Science ®Google Scholar
• Rusconi CP, Scardino E, Layzer J, RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 2002;419:90-4
   PubMed Web of Science ®Google Scholar
• Bruno JG, Kiel JL. In vitro selection of DNA aptamers to anthrax spores with electrochemiluminescence detection. Biosens Bioelectron 1999;14:457-64
   PubMed Web of Science ®Google Scholar
• Janjic N, Gold L. High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors. US20040224915; 2004
   Google Scholar
• Epstein D, Kurz JC. Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders. WO07103549 2007
   Google Scholar
• Benedict C, Diener J, Epstein D, Aptamer therapeutics useful in the treatment of complement-related disorders. US20060105980 2006
   Google Scholar
• Green C, Jones D. Methods, compositions, and kits for modulating tumor cell proliferation US20090131351; 2009
   Google Scholar
• Diener JL, Lagasse HAD, Benedict C. Aptamers to von Willebrand factor and their use as thrombotic disease therapeutics. US20090149643 2009
   Google Scholar
• Gilbert J, Hutabarat R, Schaub RG. vWF aptamer formulations and methods for use. WO08150495; 2004
   Google Scholar
• Rusconi CP, Tonkens RM. Administration of the REG1 anticoagulation system. US20090048193 2009
   Google Scholar
• Sullenger BA, Rusconi CP. Modulators of pharmacological agents US20080051339; 2008
   Google Scholar
• Rusconi CP. Steady-state subcutaneous administration of aptamers. US20090163437; 2009
   Google Scholar
• Rusconi CP. Modulators of coagulation factors. US20080153769; 2008
   Google Scholar
• Preiss JR, Wilson C, Stanton M, Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics. US20090053138 2009
   Google Scholar
• Lupold SE, Lin Y, Hicke BJ, Nucleic acid ligands to the prostate specific membrane antigen. US20050158780 2005
   Google Scholar
• Pietras K, Ostman A, Heldin C, Methods and compositions for treatment of tumors using nucleic acid ligands to platelet-derived growth factor. US20070021327 2007
   Google Scholar
• Vivekananda J, Kiel, JL. Methods and compositions for aptamers against anthrax. US6569630 2003
   Google Scholar
• Perry CM, Balfour JA. Fomivirsen. Drugs 1999;57:375-80
   PubMed Web of Science ®Google Scholar
• Ongoing clinical trial information available at http://clinicaltrials.gov/ct2/results?term=aptamer
   Google Scholar
• Bell C, Lynam E, Landfair DJ, Oligonucleotide NX1838 inhibits VEGF165-mediated cellular responses in vitro. In Vitro Cell Dev Biol Anim 1999;35:533-42
   PubMed Web of Science ®Google Scholar
• Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002;22:143-52
   PubMed Web of Science ®Google Scholar
• Ishida S, Usui T, Yamashiro K, VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci 2003;44:2155-62
   PubMed Web of Science ®Google Scholar
• Ng EW, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol 2005;40:352-68
   PubMed Web of Science ®Google Scholar
• Leung DW, Cachianes G, Kuang WJ, Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-9
   PubMed Web of Science ®Google Scholar
• Keck PJ, Hauser SD, Krivi G, Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989;246:1309-12
   PubMed Web of Science ®Google Scholar
• Asahara T, Takahashi T, Masuda H, VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 1999;18:3964-72
   PubMed Web of Science ®Google Scholar
• Csaky KG, Baffi JZ, Byrnes GA, Recruitment of marrow-derived endothelial cells to experimental choroidal neovascularization by local expression of vascular endothelial growth factor. Exp Eye Res 2004;78:1107-16
   PubMed Web of Science ®Google Scholar
• Alon T, Hemo I, Itin A, Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995;1:1024-8
   PubMed Web of Science ®Google Scholar
• Senger DR, Galli SJ, Dvorak AM, Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-5
   PubMed Web of Science ®Google Scholar
• Lamoreaux WJ, Fitzgerald ME, Reiner A, Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc Res 1998;55:29-42
   PubMed Web of Science ®Google Scholar
• Miyamoto K, Khosrof S, Bursell SE, Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). Am J Pathol 2000;156:1733-9
   PubMed Web of Science ®Google Scholar
• Jellinek D, Green LS, Bell C, Inhibition of receptor binding by high-affinity RNA ligands to vascular endothelial growth factor. Biochemistry 1994;33:10450-56
   PubMed Web of Science ®Google Scholar
• Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611
   PubMed Web of Science ®Google Scholar
• Green LS, Jellinek D, Bell C, Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor. Chem Biol 1995;2:683-95
   PubMed Web of Science ®Google Scholar
• Healy JM, Lewis SD, Kurz M, Pharmacokinetics and biodistribution of novel aptamer compositions. Pharm Res 2004;21:2234-46
   PubMed Web of Science ®Google Scholar
• Gragoudas ES, Adamis AP, Cunningham ETJr, Pegaptanib for neovascular age-related macular degeneration. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. N Engl J Med 2004;351:2805-16
   PubMed Web of Science ®Google Scholar
• Tucker CE, Chen LS, Judkins MB, Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys. J Chromatogr B Biomed Sci Appl 1999;732:203-12
   PubMed Web of Science ®Google Scholar
• Ng EW, Shima DT, Calias P, Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006;5:123-32
   PubMed Web of Science ®Google Scholar
• Trujillo CA, Nery AA, Alves JM, Development of the anti-VEGF aptamer to a therapeutic agent for clinical ophthalmology. Clin Ophthalmol 2007;1:393-402
   PubMedGoogle Scholar
• Archemix website. http://www.archemix.com/website/products.php
   Google Scholar
• Cosmi B. ARC-1779, a PEGylated aptamer antagonist of von Willebrand factor for potential use as an anticoagulant or antithrombotic agent. Curr Opin Mol Ther 2009;11:322-8
   PubMedGoogle Scholar
• Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 2007;116:2678-86
   PubMed Web of Science ®Google Scholar
• Ng EW, Shima DT, Calias P, Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006;5:123-32
   PubMed Web of Science ®Google Scholar
• Keefe AD, Schaub RG. Aptamers as candidate therapeutics for cardiovascular indications. Curr Opin Pharmacol 2008;8:147-52
   PubMedGoogle Scholar
• Dua P, Kim S, Lee DK. Patents on SELEX and therapeutic aptamers. Recent Pat DNA Gene Seq 2008;2:172-86
   PubMedGoogle Scholar
• Chan MY, Rusconi CP, Alexander JH, A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor. J Thromb Haemost 2008;6:789-96
   PubMed Web of Science ®Google Scholar
• Nimjee SM, Keys JR, Pitoc GA, A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery. Mol Ther 2006;14:408-15
   PubMedGoogle Scholar
• Dyke CK, Steinhubl SR, Kleiman NS, First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation 2006;114:2490-7
   PubMed Web of Science ®Google Scholar
• Chan MY, Cohen MG, Dyke CK, Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation 2008;117:2865-74
   PubMed Web of Science ®Google Scholar
• Regado website. http://www.regadobiosciences.com/science/clinicalresults.htm)
   Google Scholar
• Girvan AC, Teng Y, Casson LK, AGRO100 inhibits activation of nuclear factor-kappaB (NF-kappaB) by forming a complex with NF-kappaB essential modulator (NEMO) and nucleolin. Mol Cancer Ther 2006;5:1790-9
   PubMed Web of Science ®Google Scholar
• Teng Y, Girvan AC, Casson LK, AS1411 alters the localization of a complex containing protein arginine methyltransferase 5 and nucleolin. Cancer Res 2007;67:10491-500
   PubMed Web of Science ®Google Scholar
• Ireson CR, Kelland LR. Discovery and development of anticancer aptamers. Mol Cancer Ther 2006;5:2957-62
   PubMed Web of Science ®Google Scholar
• Antisoma website. http://www.antisoma.com/asm/products/as1411/
   Google Scholar
• Ostendorf T, Kunter U, Gröne HJ, Specific antagonism of PDGF prevents renal scarring in experimental glomerulonephritis. J Am Soc Nephrol 2001;12:909-18
   PubMed Web of Science ®Google Scholar
• Bergers G, Song S, Meyer-Morse N, Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111:1287-95
   PubMed Web of Science ®Google Scholar
• Song S, Ewald AJ, Stallcup W, PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol 2005;7:870-9
   PubMed Web of Science ®Google Scholar
• Sennino B, Falcón BL, McCauley D, Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102. Cancer Res 2007;67:7358-67
   PubMed Web of Science ®Google Scholar
• Jo N, Mailhos C, Ju M, Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol 2006;168:2036-53
   PubMed Web of Science ®Google Scholar
• Hicke BJ, Stephens AW, Gould T, Tumor targeting by an aptamer. J Nucl Med 2006;47:668-78
   PubMed Web of Science ®Google Scholar
• Mendonsa SD, Bowser MT. In vitro selection of high-affinity DNA ligands for human IgE using capillary electrophoresis. Anal Chem 2004;76:5387-92
   PubMed Web of Science ®Google Scholar
• Balasubramanian V, Nguyen LT, Balasubramanian SV, Interferon-gamma-inhibitory oligodeoxynucleotides alter the conformation of interferon-gamma. Mol Pharmacol 1998;53:926-32
   PubMedGoogle Scholar
• Lee JF, Stovalla GM, Ellington AD, Aptamer therapeutics advance. Curr Opin Chem. Biol 2006;10:282-9
   Google Scholar
• Yoshida Y, Sakai N, Masuda H, Rabbit antibody detection with RNA aptamers. Rabbit antibody detection with RNA aptamers. Anal Biochem 2008;375:217-22
   PubMedGoogle Scholar
• The catalog of all available aptamers done by Ellington and his research group is available at http://aptamer.icmb.utexas.edu/
   Google Scholar
• Lee JF, Hesselberth JR, Meyers LA, Aptamer database. Nucleic Acids Res 2004;32:D95-100
   PubMed Web of Science ®Google Scholar
• Farokhzad OC, Jon S, Khademhosseini A, Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res 2004;64:7668-72
   PubMed Web of Science ®Google Scholar
• McNamara JO II, Andrechek ER, Wang Y, Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 2006;24:1005-15
   PubMed Web of Science ®Google Scholar
• Farokhzad OC, Cheng J, Teply BA, Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 2006;103:6315-20
   PubMed Web of Science ®Google Scholar
• More details about patents are available at http://apps.isiknowledge.com/DIIDW_GeneralSearch_input.do?product=DIIDW&SID=Z2naOeJ8271P598d7L1& search_mode=GeneralSearch
   Google Scholar
• Akiyama H, Kachi S, Silva RL, Intraocular injection of an aptamer that binds PDGF-B: a potential treatment for proliferative retinopathies. J Cell Physiol 2006;207:407-12
   PubMed Web of Science ®Google Scholar
• Beri A, Punnam SR. Anticoagulation in patients with acute ischemic stroke and atrial fibrillation--a balance of risks and benefits. Cardiovasc Drugs Ther 2008;22:419-25
   PubMedGoogle Scholar
• Trent JO, Bates PJ, Miller DM. Anti-proliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin. US20080318890 2008
   Google Scholar
• Hicke B, Warren S, Parma D. Tenascin-C nucleic acid ligands. US20060105378 2006
   Google Scholar
• Diener JL, Wagner-Whyte J, Fontana D. Aptamers that bind thrombin with high affinity. WO07025049 2007
   Google Scholar
• Friebe M, Hecht M, Dinkelborg L, Aptamers labelled with gallium-68. WO08028534 2008
   Google Scholar